Difference between revisions of "Trastuzumab (Herceptin)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.herceptin.com/pdf/herceptin-prescribing.pdf Trastuzumab (Herceptin) package insert]</ref><ref>[http://hemo...") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.herceptin.com/pdf/herceptin-prescribing.pdf Trastuzumab (Herceptin) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/trastuzumab.pdf Trastuzumab (Herceptin) package insert (locally hosted backup)]</ref> | + | Class/mechanism: HER2/neu receptor antagonist, humanized IgG1 kappa monoclonal antibody. Trastuzumab binds to the extracellular domain of HER2/erbB2 (human epidermal growth factor receptor 2), which is overexpressed in certain malignancies. Trastuzumab helps to mediate antibody-dependent cellular cytotoxicity (ADCC) preferentially against cells that overexpress HER2.<ref name="insert">[http://www.herceptin.com/pdf/herceptin-prescribing.pdf Trastuzumab (Herceptin) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/trastuzumab.pdf Trastuzumab (Herceptin) package insert (locally hosted backup)]</ref><ref>[http://www.herceptin.com Herceptin manufacturer's website]</ref> |
| − | <br>Route: | + | <br>Route: IV |
| − | <br>Extravasation: | + | <br>Extravasation: no information |
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>. |
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://www.herceptin.com/breast/herceptin/ Trastuzumab (Herceptin) manufacturer's patient website]<ref>[http://www.herceptin.com/breast/herceptin/ Trastuzumab (Herceptin) manufacturer's patient website]</ref> | ||
*[http://chemocare.com/bio/trastuzumab.asp Trastuzumab (Herceptin) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/trastuzumab.asp Trastuzumab (Herceptin) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/trastuzumab.asp Trastuzumab (Herceptin) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/trastuzumab.asp Trastuzumab (Herceptin) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/trastuzumab-patient-drug-information Trastuzumab (Herceptin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/trastuzumab-patient-drug-information Trastuzumab (Herceptin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/trastuzumab-patient-drug-information Trastuzumab (Herceptin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/trastuzumab-patient-drug-information Trastuzumab (Herceptin) patient drug information (UpToDate)]</ref> | ||
Revision as of 00:23, 26 February 2012
General information
Class/mechanism: HER2/neu receptor antagonist, humanized IgG1 kappa monoclonal antibody. Trastuzumab binds to the extracellular domain of HER2/erbB2 (human epidermal growth factor receptor 2), which is overexpressed in certain malignancies. Trastuzumab helps to mediate antibody-dependent cellular cytotoxicity (ADCC) preferentially against cells that overexpress HER2.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Patient drug information
- Trastuzumab (Herceptin) manufacturer's patient website[4]
- Trastuzumab (Herceptin) patient drug information (Chemocare)[5]
- Trastuzumab (Herceptin) patient drug information (UpToDate)[6]
References
- ↑ 1.0 1.1 Trastuzumab (Herceptin) package insert
- ↑ Trastuzumab (Herceptin) package insert (locally hosted backup)
- ↑ Herceptin manufacturer's website
- ↑ Trastuzumab (Herceptin) manufacturer's patient website
- ↑ Trastuzumab (Herceptin) patient drug information (Chemocare)
- ↑ Trastuzumab (Herceptin) patient drug information (UpToDate)